Reduced dopaminergic function in alcoholics is related to severe dependence.
With a view to the role of dopamine (DA) systems in reward processes and considering recent studies linking specific alleles at the DA-D2 receptor gene locus with alcoholism (especially with severe types) dopaminergic functions were evaluated in 49 alcoholics using growth hormone (GH) response to DA receptor agonist apomorphine (0.01 mg/kg subcutaneously). neuroendocrine testing was performed (during intoxication) at the time of admission to an inpatient alcohol treatment program and was repeated 7 days later (in a postintoxicated state). Patients underwent clinical examination, detoxification treatment and a subsequent rehabilitation program for abstinence including follow-up evaluation of outcome for 6 months. A two-factor analysis of variance (ANOVA) revealed a significant change of GH response (peak values corrected for baseline) over time (between intoxication and postintoxication; p < 0.001) and between abstainers and relapsers (p = 0.032). Relapse was also associated with paternal alcoholism, early onset of disease, and a more complete dependence syndrome and cerebellar atrophy. Standardized canonical discriminant coefficient was highest for reduced GH response compared to other relapse predictors in the model used. It is concluded that reduced GH response to dopaminergic stimulation corresponds to a progressed stage or syndrome of severe alcohol dependence; however, if reduced, dopaminergic function is one cause or consequence of addiction in this particular subgroup of patients that remains to be elucidated.
Schmidt
L G
LG
Department of Psychiatry and Medicine, Free University of Berlin, Germany.
Dettling
M
M
Graef
K J
KJ
Heinz
A
A
Kuhn
S
S
Podschus
J
J
Rommelspacher
H
H
D000328:Adult; D000437:Alcoholism / Q000175:diagnosis / Q000503:physiopathology* / Q000534:rehabilitation; D001058:Apomorphine; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D013695:Temperance; D016896:Treatment Outcome
D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D013006:Growth Hormone; D001058:Apomorphine; D004298:Dopamine